The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback